Vericel Corp

NASDAQ:VCEL  
52.65
-0.45 (-0.85%)
Products

Vericel Announces FDA Acceptance Of Biologics License Application For NexoBrid

Published: 09/16/2020 13:30 GMT
Vericel Corp (VCEL) - Vericel Announces FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns.
Vericel Corp - FDA Assigned a Prescription Drug User Fee Act (pdufa) Target Date of June 29, 2021.
Vericel Corp - FDA Communicated That It is Not Currently Planning to Hold an Advisory Committee Meeting to Discuss Application for Nexobrid.